Partnership for better healthcare solution against AMR
A third largest well known pharmaceutical company in India, Cipla Ltd acquired novel and patented anti-infective drug, Elores from Venus Remedies Ltd (VRL). Currently, Cipla is the market leader in the anti-infective segment in India. The company’s agenda behind this acquisition is to contribute to the fight against Anti-Microbial Resistance (AMR) and strengthen its presence in the branded Indian critical care department.
This product was launched in India across selected hospitals in the country in 2013 after approval from the Drug Controller General of India, Cipla stated. AMR has emerged as a life-threatening experience to public health, at present it is estimated that 10 million individuals worldwide could die annually from complications related to AMR. India is also suffering from one of the largest problems of drug-resistant bacteria. In India, Cipla has a long history for antibiotic development. Most recently, Cipla introduced the most effective antibiotic colistin in India. Flores will strengthen Cipla’s performance in the anti-infective department.
Elores drug for patient’s health
Elores is novel combination of Ceftriaxone (a third-generation beta lactum cephalosporin), Sulbactum (a beta lactamase inhibitor) and disodium EDTA, and antibiotic resistance breaker indicated for treatment of life threatening infections caused be gram negative bacteria.
VRL has been leading the research on novel anti-infective in India. AMR is a huge public health crisis that immediately needs to deal with and at all levels of healthcare setups. Elores provides a solution for this and it is very satisfying to see the difference that made in patient’s health. It gives good hope that the consistency efforts of Elores in this space will lead to better outcomes on patient’s health.
Cipla Managing Director and Global Chief Executive Officer Umang Vohra said, “Cipla has consistently been at the forefront of promoting the rational and judicious use of antibiotics, and has been a leading industry voice in the fight against AMR. Elores underscores our commitment to anti-microbial stewardship and is a significant addition to our branded portfolio of anti-infective in India. We recently acquired ZEMDRI, and with the acquisition of Elores, we have added to our offering of new generation antibiotics. In keeping with our purpose of Caring for Life, Elores will improve patient access to innovative quality medicines and help patients battle life-threatening resistance at critical junctures.”
